KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.

Advanced Pancreatic Ductal Adenocarcinoma Clinical Trial

Official title:
A Multicenter, Randomized, Double-Blind Phase III Study to Assess the Efficacy and Safety of KN046 Combined With Gemcitabine and Nab-Paclitaxel Versus Placebo Combined With Gemcitabine and Nab-Paclitaxel in First Line Advanced Pancreatic Ductal Adenocarcinoma Subjects (ENREACH-PDAC-01).

Status Active, not recruiting

Clinical Trial Summary

This study is a multicenter, randomized, double-Blind Phase III Study to compare the clinical efficacy and safety of KN046 plus gemcitabine and nab-paclitaxel versus placebo plus gemcitabine and nab-paclitaxel in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adenocarcinoma
Advanced Pancreatic Ductal Adenocarcinoma

Clinical Trial Details

NCT number	NCT05149326
Study type	Interventional
Source	Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	January 20, 2022
Completion date	August 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02921022` - Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma	N/A
Not yet recruiting	`NCT06206876` - FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma	Phase 1
Recruiting	`NCT04887805` - Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer	Phase 2
Not yet recruiting	`NCT05632328` - AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer	Phase 2